Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.

Oncotarget - 8 Dec 2015

Tung Min-Che, Lin Po-Lin, Wang Yao-Chen, He Tsung-Ying, Lee Ming-Ching, Yeh Sauh D, Chen Chih-Yi, Lee Huei

Abstract excerpt

Nrf2 is a key transcription factor for genes coding for antioxidants, detoxification enzymes, and multiple drug resistance and it also confers resistance to anticancer drugs. Here, we hypothesized that mutant p53 could upregulate Nrf2 expression at the transcriptional level, thereby conferring cisplatin resistance in non-small cell lung cancer (NSCLC). Luciferase reporter assays and real-time PCR analysis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to bcl-X Protein
Share to Cisplatin
Share to Kaplan-Meier Estimate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to NF-E2-Related Factor 2

Share to Proportional Hazards Models

Share to Proto-Oncogene Proteins c-bcl-2

Share to Sp1 Transcription Factor

Share to Up-Regulation

Source

Open in PubMed Open full text

Identifiers

PMID: 26497680
DOI: 10.18632/oncotarget.6150
PMCID: PMC4747182

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.PMID 26497680Read ↗

The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cellsSemantic proximity Read ↗

[Role of the expression level of Nrf2 in predicting response of EGFR-TKIs in lung adenocarcinoma patients with EGFR gene mutations].Semantic proximity Read ↗

KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?Semantic proximity Read ↗

RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.Semantic proximity Read ↗

Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.Semantic proximity Read ↗

Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.Semantic proximity Read ↗

The involvement of NRF2 in lung cancer.Semantic proximity Read ↗

Mutation of the Nrf2 gene in non-small cell lung cancer.Semantic proximity Read ↗

Molecular mechanisms and systemic targeting of NRF2 dysregulation in cancer.Semantic proximity Read ↗

Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters.Semantic proximity Read ↗

Oncogenic KRAS confers chemoresistance by upregulating NRF2.Semantic proximity Read ↗

The Dual Roles of NRF2 in Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.